+

WO2003027320A3 - Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1 - Google Patents

Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1 Download PDF

Info

Publication number
WO2003027320A3
WO2003027320A3 PCT/IB2002/004123 IB0204123W WO03027320A3 WO 2003027320 A3 WO2003027320 A3 WO 2003027320A3 IB 0204123 W IB0204123 W IB 0204123W WO 03027320 A3 WO03027320 A3 WO 03027320A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
treatment
pik3r1
methods
diseases associated
Prior art date
Application number
PCT/IB2002/004123
Other languages
French (fr)
Other versions
WO2003027320A2 (en
Inventor
Finn Skou Pedersen
Annette Balle Soerensen
Anne Ahlmann Nielsen
Original Assignee
Univ Aarhus
Finn Skou Pedersen
Annette Balle Soerensen
Anne Ahlmann Nielsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/963,131 external-priority patent/US20030224460A1/en
Priority claimed from US09/962,854 external-priority patent/US20030044803A1/en
Priority claimed from US09/962,855 external-priority patent/US20020164576A1/en
Priority claimed from US09/962,929 external-priority patent/US20020115058A1/en
Application filed by Univ Aarhus, Finn Skou Pedersen, Annette Balle Soerensen, Anne Ahlmann Nielsen filed Critical Univ Aarhus
Priority to AU2002329000A priority Critical patent/AU2002329000A1/en
Publication of WO2003027320A2 publication Critical patent/WO2003027320A2/en
Publication of WO2003027320A3 publication Critical patent/WO2003027320A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel sequences for use in diagnosis and treatment of lymphoma and leukemia. In addition, the present invention describes the use of novel compositions for use in screening methods.
PCT/IB2002/004123 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1 WO2003027320A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002329000A AU2002329000A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US09/963,131 US20030224460A1 (en) 2000-09-22 2001-09-24 Novel compositions and methods for lymphoma and leukemia
US09/962,854 2001-09-24
US09/962,929 2001-09-24
US09/963,131 2001-09-24
US09/962,916 2001-09-24
US09/962,854 US20030044803A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US09/962,855 US20020164576A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
US09/962,916 US20030077590A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
US09/962,855 2001-09-24
US09/962,929 US20020115058A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1

Publications (2)

Publication Number Publication Date
WO2003027320A2 WO2003027320A2 (en) 2003-04-03
WO2003027320A3 true WO2003027320A3 (en) 2003-10-23

Family

ID=27542309

Family Applications (5)

Application Number Title Priority Date Filing Date
PCT/IB2002/004158 WO2003027321A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
PCT/IB2002/004123 WO2003027320A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1
PCT/IB2002/004134 WO2003027276A2 (en) 2001-09-24 2002-09-24 Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
PCT/IB2002/004197 WO2003027295A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of jak1
PCT/IB2002/005830 WO2003043565A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of nrf2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/004158 WO2003027321A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin

Family Applications After (3)

Application Number Title Priority Date Filing Date
PCT/IB2002/004134 WO2003027276A2 (en) 2001-09-24 2002-09-24 Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
PCT/IB2002/004197 WO2003027295A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of jak1
PCT/IB2002/005830 WO2003043565A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of nrf2

Country Status (2)

Country Link
AU (4) AU2002329000A1 (en)
WO (5) WO2003027321A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2614110A1 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
US20090215876A1 (en) * 2006-02-14 2009-08-27 King Randall W Mitotic Progression Genes and Methods of Modulating Mitosis
US20220306688A1 (en) * 2019-06-07 2022-09-29 Emory University KRAS G12V Mutant Binds to JAK1, Inhibitors, Pharmaceutical Compositions, and Methods Related Thereto

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020126A1 (en) * 1996-11-01 1998-05-14 Onyx Pharmaceuticals, Inc. Nucleotide sequences that encode phosphatidylinositol-3' kinase associated proteins and uses thereof
WO2001000881A1 (en) * 1999-06-25 2001-01-04 Isis Pharmaceuticals, Inc. Antisense modulation of pi3k p85 expression
WO2001081346A2 (en) * 2000-04-25 2001-11-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2001083481A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2002040637A2 (en) * 2000-11-20 2002-05-23 Isis Pharmaceuticals, Inc. Antisense modulation of pi3k p85 expression

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ237669A (en) * 1990-04-13 1992-08-26 Res Dev Foundation T-cell proteins expressed in t-cell development and their preparation
US5821069A (en) * 1993-06-30 1998-10-13 Ludwig Institute For Cancer Research Method for determining tyrosine kinase in a sample
US6300058B1 (en) * 1992-01-29 2001-10-09 Hitachi Chemical Research Center, Inc. Method for measuring messenger RNA
WO1997003358A1 (en) * 1995-07-07 1997-01-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of identifying inhibitors of the jak-stat signal transduction pathway
WO1998016557A1 (en) * 1996-10-11 1998-04-23 The General Hospital Corporation Assays for g-protein-linked receptors
CA2290738A1 (en) * 1997-05-21 1998-11-26 Clontech Laboratories, Inc. Nucleic acid arrays
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
WO1999038972A2 (en) * 1998-01-28 1999-08-05 Chiron Corporation Human genes and gene expression products ii
WO1999041985A1 (en) * 1998-02-23 1999-08-26 Quark Biotech, Inc. P53-dependent secretion of growth inhibitory factors
DE69918089T2 (en) * 1998-04-17 2005-07-14 Parker Hughes Institute, St. Paul BTK INHIBITORS AND METHODS OF IDENTIFICATION AND USE
DE19817947A1 (en) * 1998-04-17 1999-10-28 Metagen Gesellschaft Fuer Genomforschung Mbh New nucleic acid sequences expressed in uterine myoma, and derived polypeptides, for treatment of uterine carcinoma and identification of therapeutic agents
WO1999065928A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
JP2002536963A (en) * 1998-12-22 2002-11-05 ミリアド・ジェネティックス・インコーポレイテッド Protein-protein interaction in neurodegenerative diseases
US6110664A (en) * 1999-06-25 2000-08-29 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-S1 expression
GB9917165D0 (en) * 1999-07-22 1999-09-22 Knoll Ag Polypeptides polynuclcotides and uses thereof
EE200200123A (en) * 1999-09-10 2003-08-15 Merck & Co., Inc. A tyrosine kinase inhibiting compound, a pharmaceutical composition comprising it, and a therapeutic use
EP1226280A4 (en) * 1999-10-25 2003-10-15 Univ Princeton GENETIC SEQUENCES ASSOCIATED WITH NEURAL CELL PROLIFERATION AND DISEASES
WO2001034633A2 (en) * 1999-11-12 2001-05-17 Fred Hutchinson Cancer Research Center Methods for treatment of human huntington's disease and methods of screening for active agents
WO2001051670A2 (en) * 2000-01-07 2001-07-19 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
GB2375172A (en) * 2000-02-07 2002-11-06 Quark Biotech Inc Fas pathway genes
CA2411278A1 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US6794137B2 (en) * 2000-09-08 2004-09-21 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
AU2001290699A1 (en) * 2000-09-08 2002-03-22 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
WO2002022884A2 (en) * 2000-09-12 2002-03-21 Transgenetics Incorporated Microarrayed organization of transcription factor target genes
CA2418724A1 (en) * 2000-09-13 2002-03-21 Archemix Corporation Target activated nucleic acid biosensor and methods of using same
WO2002059367A2 (en) * 2000-11-30 2002-08-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
DE60232059D1 (en) * 2001-03-01 2009-06-04 Epigenomics Ag METHOD FOR DEVELOPING SKILLS FOR DIAGNOSTIC AND THERAPEUTIC USES BASED ON THE EXPRESSION AND METHYLATION STATUS OF THE GENES
CA2459219A1 (en) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
GB0122914D0 (en) * 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020126A1 (en) * 1996-11-01 1998-05-14 Onyx Pharmaceuticals, Inc. Nucleotide sequences that encode phosphatidylinositol-3' kinase associated proteins and uses thereof
WO2001000881A1 (en) * 1999-06-25 2001-01-04 Isis Pharmaceuticals, Inc. Antisense modulation of pi3k p85 expression
WO2001081346A2 (en) * 2000-04-25 2001-11-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2001083481A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2002040637A2 (en) * 2000-11-20 2002-05-23 Isis Pharmaceuticals, Inc. Antisense modulation of pi3k p85 expression

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BAI RENYUAN Y ET AL: "NPM-ALK associated with anaplastic large-cell lymphoma activates the PI3-kinase/Akt antiapoptotic signaling pathway.", BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), 42nd Annual Meeting of the American Society of Hematology;San Francisco, California, USA; December 01-05, 2000, pages 469a, XP008019458, ISSN: 0006-4971 *
BORLADO LUIS R ET AL: "Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.", FASEB JOURNAL, vol. 14, no. 7, May 2000 (2000-05-01), pages 895 - 903, XP002246866, ISSN: 0892-6638 *
FRUMAN DAVID A ET AL: "Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85-alpha gene.", GENOMICS, vol. 37, no. 1, 1996, pages 113 - 121, XP002246862, ISSN: 0888-7543 *
HARRIS N L ET AL: "New approaches to lymphoma diagnosis.", HEMATOLOGY / THE EDUCATION PROGRAM OF THE AMERICAN SOCIETY OF HEMATOLOGY. AMERICAN SOCIETY OF HEMATOLOGY. EDUCATION PROGRAM. UNITED STATES 2001, 2001, pages 194 - 220, XP002246868, ISSN: 1520-4391 *
HOFMANN WOLF-K ET AL: "Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray.", BLOOD, vol. 98, no. 3, 1 August 2001 (2001-08-01), pages 787 - 794, XP002246867, ISSN: 0006-4971 *
LIN XIONGBIN ET AL: "Overexpression of phosphatidylinositol 3-kinase in human lung cancer.", LANGENBECK'S ARCHIVES OF SURGERY, vol. 386, no. 4, July 2001 (2001-07-01), pages 293 - 301, XP002246865, ISSN: 1435-2443 *
SKOLNIK E Y ET AL: "Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of traget proteins for receptor tyrosine kinases", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 65, no. 1, 5 April 1991 (1991-04-05), pages 83 - 90, XP002100383, ISSN: 0092-8674 *
SNYDER R C ET AL: "Increased levels of the p85alpha regulatory subunit of phosphatidylinositol 3-OH kinase in cell lysates of juvenile myelomonocytic leukemia cells.", BLOOD, vol. 90, no. 10 SUPPL. 1 PART 1, 15 November 1997 (1997-11-15), 39th Annual Meeting of the American Society of Hematology;San Diego, California, USA; December 5-9, 1997, pages 411A, XP008019234, ISSN: 0006-4971 *
SUN MEI ET AL: "Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.", CANCER RESEARCH, vol. 61, no. 16, 15 August 2001 (2001-08-15), pages 5985 - 5991, XP002246863, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2003027276A3 (en) 2004-02-12
AU2002329000A1 (en) 2003-04-07
WO2003027321A3 (en) 2003-11-06
AU2002337442A1 (en) 2003-04-07
WO2003027276A2 (en) 2003-04-03
WO2003027295A2 (en) 2003-04-03
AU2002364889A1 (en) 2003-06-10
AU2002364889A8 (en) 2003-06-10
WO2003043565A2 (en) 2003-05-30
AU2002330713A1 (en) 2003-04-07
WO2003027320A2 (en) 2003-04-03
WO2003043565A3 (en) 2003-11-13
WO2003027295A3 (en) 2003-10-16
WO2003027321A2 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
WO2003008583A3 (en) Novel compositions and methods for cancer
EP2014669A3 (en) Compositions and methods for cancer
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
WO2005027966A3 (en) Antibodies with altered effector functions
WO2003045230A3 (en) Novel compositions and methods for cancer
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2003049702A8 (en) Vanilloid receptor ligands and their use in treatments
WO2004034990A3 (en) Methods and compositions for use in treating cancer
WO2005063734A3 (en) Substituted thiophenes
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
GB0111186D0 (en) Novel compounds
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
SG167670A1 (en) Aminocyclohexyl ether compounds and uses thereof
WO2003057146A3 (en) Novel compositions and methods for cancer
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
WO2004091490A3 (en) Somatostatin-dopamine chimeric analogs
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
WO2003053224A3 (en) Novel compositions and methods for cancer
WO2002024867A3 (en) Novel compositions and methods for lymphoma and leukemia
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2003035837A3 (en) Novel compositions and methods for cancer
CA2436572A1 (en) Perylenequinones for use as photosensitizers and sonosensitizers
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载